Almost five years after the first patient-powered approvals for Clinuvel Pharmaceuticals Ltd.'s Scenesse (afamelanotide) arrived in Europe, the FDA has granted the company U.S. approval to increase pain-free light exposure in adults with a history of skin damage from the rare inherited disorder erythropoietic protoporphyria (EPP).